Single-center Study Comparing Short and Mid-Term Results of EVAR in Old and Young Populations
Abstract Objective: The purpose of this study was to compare the operative mortality rate and outcomes of endovascular aneurysm repair (EVAR) between young and geriatric people in a single center. Methods: Eighty-five patients with abdominal aortic aneurysms who underwent EVAR between January 2012 and September 2016 were included. Outcomes were compared between two groups: the young (aged
The three randomized trials comparing endovascular aneurysm repair (rEVAR) with open surgical repair (rOSR) of ruptured abdominal aortic aneurysm (rAAA) were poorly designed and heavily criticized. The short- and long-term survival advantages of rEVAR remain unclear. We sought to compare the two treatment modalities using a propensity-matched analysis in a real-world setting.
The objective of this study was to report the 5-year outcomes of the Food and Drug Administration investigational device exemption clinical trial of endovascular aneurysm repair (EVAR) with the Ovation (Endologix, Irvine, Calif) stent graft for elective treatment of abdominal aortic aneurysm (AAA).
This study evaluates 30-day mortality after endovascular aneurysm repair (EVAR) vs open repair for ruptured complex abdominal aortic aneurysms (AAAs), including juxtarenal, pararenal, and suprarenal AAAs and extent IV thoracoabdominal aortic aneurysms, in a real-world setting.
The use of endovascular aneurysm repair (EVAR) has changed the treatment algorithm for patients with ruptured abdominal aortic aneurysms (RAAAs). Whereas the overall incidence of RAAA is declining, the proportion of patients treated with EVAR in contemporary practice in the United States is unknown. Therefore, we described the change in incidence, treatment pattern, and outcomes of RAAA using the National Inpatient Sample database from 2004 to 2015.
Reintervention after endovascular aneurysm repair (EVAR) is common. However, the financial impact of reintervention after EVAR on the national scale is poorly understood. Our objective was to describe the overall reimbursement for aneurysm treatment (EVAR plus reinterventions) among a cohort of patients with known follow-up for 5 years after repair.
The management of ruptured abdominal aortic aneurysm (AAA) has changed during the past several years. Numerous studies have shown conflicting results for the role of endovascular aneurysm repair (EVAR) in ruptured AAA. In light of this, we have compared the outcomes from EVAR with those of open repair.
Endovascular aneurysm repair (EVAR) has become the preferred mode for treatment of abdominal aortic aneurysms (AAAs) despite a higher incidence of secondary interventions because of endoleak and late aneurysm-related mortality. In particular, large AAAs have been shown to have worse outcomes after EVAR compared with small AAAs. The reasons for this are unclear. Our objective was to determine the effect of AAA size on the incidence of endoleak, secondary interventions during post-EVAR follow-up, and overall survival.
Endovascular abdominal aortic aneurysm repair (EVAR) is commonly used to treat abdominal aortic aneurysm (AAA). However, the incidence of long-term complications and the need for re-interventions after EVAR remains a concern. Newer generation stent grafts have encouraging short and mid-term outcomes, but thorough analysis of their long-term performance is necessary.
Post-hospital syndrome (PHS) is an acquired, transient period of health vulnerability that follows hospital admission for acute illness. It is characterized by physiologic deconditioning secondary to stressors from disruption in circadian rhythm, depletion of nutritional reserve, and pain or discomfort associated with hospitalization. PHS is reported as an independent risk factor for readmission and adverse postoperative outcomes. The aim of this study was to investigate whether PHS affects outcomes of elective endovascular aneurysm repair (EVAR) of abdominal aortic aneurysm.
CONCLUSION: TF-TAVI can be performed successfully in patients with aortic disease or previous endovascular aortoiliac intervention. Simultaneous and sequential (T)EVAR is feasible. PMID: 31416046 [PubMed - as supplied by publisher]